Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical progress and pharmacology of small molecule bromodomain inhibitors

11 Jun 2016

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27295577
DOI: 10.1016/j.cbpa.2016.05.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical progress and pharmacology of small molecule bromodomain inhibitorsPMID 27295577Read ↗

Bromodomains: Structure, function and pharmacology of inhibitionSemantic proximity Read ↗

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseasesSemantic proximity Read ↗

Small-Molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic PotentialSemantic proximity Read ↗

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) ProteinsSemantic proximity Read ↗

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read ↗

Bromodomains as therapeutic targets in cancerSemantic proximity Read ↗

Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target ValidationSemantic proximity Read ↗

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain InhibitorsSemantic proximity Read ↗

Targeting bromodomain-containing proteins: research advances of drug discoverySemantic proximity Read ↗

The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorSemantic proximity Read ↗

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.